Kazia Therapeutics Limited (KZIA)

0.2720 -0.0105 (-3.72%) At close: 04:00PM EDT

Kazia Therapeutics Limited

Three International Towers
Level 24 300 Barangaroo Avenue
Sydney, NSW 2000
Australia

https://www.kaziatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. John Edwin Friend II, M.D.	CEO, MD & Director	728.47k	N/A	1970
Ms. Gabrielle Heaton BBUS (ACC), CPA	Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer	177.91k	N/A	N/A
Ms. Anna Sandham	Company Secretary	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

Corporate Governance

Kazia Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.